Ferraro, Pietro Manuel http://orcid.org/0000-0002-1379-022X
Caletti, Chiara
Capolongo, Giovanna
Lombardi, Marco
Scolari, Francesco
Vezzoli, Giuseppe
Vitale, Corrado
Gambaro, Giovanni
Funding for this research was provided by:
Alnylam Pharmaceuticals
Università Cattolica del Sacro Cuore
Article History
Received: 9 January 2023
Accepted: 30 May 2023
First Online: 26 June 2023
Declarations
:
: PMF received consultant fees and grant/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, BioHealth Italia, Gilead, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate; PMF is a member of the European Reference Network for Rare Kidney Diseases (ERKNet)—Project ID No 739532; CC nothing to declare; GC nothing to declare; ML nothing to declare; FS nothing to declare; GV nothing to declare; CV nothing to declare; GG received consultant and lecture fees from Alfa Sigma, Alnylam, Alexion, Astellas, AstraZeneca, Baxter, Eureka, Medtronic, Vifor Pharma, research grants from Iperboreal and Roche Diagnostics, and royalties as an author for UpToDate.
: This article does not contain any studies with human participants or animals performed by any of the Authors.
: For this type of study formal consent is not required.